Amendment No.5 to Schedule 13D

0001193125-14-207597.txt : 20140521 0001193125-14-207597.hdr.sgml : 20140521 20140521105224 ACCESSION NUMBER: 0001193125-14-207597 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20140521 DATE AS OF CHANGE: 20140521 GROUP MEMBERS: PS MANAGEMENT GP,LLC GROUP MEMBERS: WILLIAM A. ACKMAN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALLERGAN INC CENTRAL INDEX KEY: 0000850693 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 951622442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-40724 FILM NUMBER: 14859881 BUSINESS ADDRESS: STREET 1: 2525 DUPONT DRIVE CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 7142464500 MAIL ADDRESS: STREET 1: P.O. BOX 19534 CITY: IRVINE STATE: CA ZIP: 92713-9534 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Pershing Square Capital Management, L.P. CENTRAL INDEX KEY: 0001336528 IRS NUMBER: 383694136 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 888 SEVENTH AVENUE STREET 2: 42ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 212-813-3700 MAIL ADDRESS: STREET 1: 888 SEVENTH AVENUE STREET 2: 42ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 SC 13D/A 1 d729305dsc13da.htm AMENDMENT NO.5 TO SCHEDULE 13D Amendment No.5 to Schedule 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934

Amendment No. 5

ALLERGAN, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

018490102

(CUSIP Number)

Roy J. Katzovicz, Esq.

Pershing Square Capital Management, L.P.

888 Seventh Avenue, 42nd Floor

New York, New York 10019

212-813-3700

with a copy to:

Stephen Fraidin, Esq.

Richard M. Brand, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

212-446-4800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 21, 2014

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)


CUSIP No. 018490102		13D		Page 2 of 7 Pages


1	NAME OF REPORTING PERSON Pershing Square Capital Management, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS) OO (See Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 28,878,538
		9	SOLE DISPOSITIVE POWER 0
		10	SHARED DISPOSITIVE POWER 28,878,538
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 28,878,638
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.7%(1)%
14	TYPE OF REPORTING PERSON IA

(1)	Calculated based on 297,556,619 shares of common stock, $0.01 par value, of Allergan, Inc., outstanding as of May 1, 2014, as reported in Allergan, Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2014, as filed with the Securities and Exchange Commission on May 7, 2014.

Page 2 of 7 Pages


CUSIP No. 018490102		13D		Page 3 of 7 Pages


1	NAMES OF REPORTING PERSON PS Management GP, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS* OO (See Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 28,878,538
		9	SOLE DISPOSITIVE POWER 0
		10	SHARED DISPOSITIVE POWER 28,878,538
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 28,878,638
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.7%(2)
14	TYPE OF REPORTING PERSON OO

(2)	Calculated based on 297,556,619 shares of common stock, $0.01 par value, of Allergan, Inc., outstanding as of May 1, 2014, as reported in Allergan, Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2014, as filed with the Securities and Exchange Commission on May 7, 2014.

Page 3 of 7 Pages


CUSIP No. 018490102		13D		Page 4 of 7 Pages


1	NAME OF REPORTING PERSON William A. Ackman
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS) OO (See Item 3)
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 28,878,538
		9	SOLE DISPOSITIVE POWER 0
		10	SHARED DISPOSITIVE POWER 28,878,538
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 28,878,638
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.7%(3)%
14	TYPE OF REPORTING PERSON IN

(3)	Calculated based on 297,556,619 shares of common stock, $0.01 par value, of Allergan, Inc., outstanding as of May 1, 2014, as reported in Allergan, Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2014, as filed with the Securities and Exchange Commission on May 7, 2014.

Page 4 of 7 Pages


CUSIP No. 018490102		13D		Page 5 of 7 Pages

Item 1.

Security and Issuer.

This amendment No. 5 to Schedule 13D (this “Amendment No. 5”), which amends and supplements the statement on Schedule 13D filed on April 21, 2014 (the “Original 13D”), as amended and supplemented by amendment No. 1 (“Amendment No. 1”), filed on May 2, 2014, amendment No. 2 (“Amendment No. 2”), filed on May 5, 2014, amendment No. 3 (“Amendment No. 3”), filed on May 12, 2014, and amendment No. 4 (“Amendment No. 4”), filed on May 19, 2014 (the Original 13D as amended and supplemented by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and this Amendment No. 5, the “Schedule 13D”), by (i) Pershing Square Capital Management, L.P., a Delaware limited partnership (“Pershing Square”); (ii) PS Management GP, LLC, a Delaware limited liability company (“PS Management”) and (iii) William A. Ackman, a citizen of the United States (together with Pershing Square and PS Management, the “Reporting Persons”) relates to the common stock, par value $0.01 per share (the “Common Stock”), of Allergan, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at: 2525 Dupont Drive, Irvine, California, 92612.

Capitalized terms not defined in this Amendment No. 5 shall have the meaning ascribed to them in the Schedule 13D. Except as set forth herein, the Schedule 13D is unmodified.

Item 4.

Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following information:

On May 21, 2014, Pershing Square sent a letter to the Issuer’s Board of Directors. The letter is attached as Exhibit 99.8 and incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits.


Exhibit 99.8		Letter to Allergan, Inc. Board of Directors from Pershing Square Capital Management, L.P., dated as of May 21, 2014.

Page 5 of 7 Pages


CUSIP No. 018490102		13D		Page 6 of 7 Pages

SIGNATURES

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: May 21, 2014


PERSHING SQUARE CAPITAL MANAGEMENT, L.P.

By:	PS Management GP, LLC, its General Partner

	By:	/s/ William A. Ackman
	Name:	William A. Ackman
	Title:	Managing Member

PS MANAGEMENT GP, LLC

By:	/s/ William A. Ackman
Name:	William A. Ackman
Title:	Managing Member

By:	/s/ William A. Ackman
Name:	William A. Ackman

Page 6 of 7 Pages


CUSIP No. 018490102		13D		Page 7 of 7 Pages

EXHIBIT INDEX


Exhibit		Description

Exhibit 99.1		Joint Filing Agreement, dated as of April 21, 2014, among Pershing Square Capital Management, L.P., PS Management GP, LLC and William A. Ackman.*

Exhibit 99.2		Trading data.*

Exhibit 99.3		Letter Agreement, dated as of February 25, 2014, among Pershing Square Capital Management, L.P. and Valeant Pharmaceuticals International, Inc.*

Exhibit 99.4		Amended and Restated Limited Liability Company Agreement of PS Fund 1, LLC, dated as of April 3, 2014, by and among Pershing Square Capital Management, L.P., Pershing Square L.P., Pershing Square II, L.P., Pershing Square International, Ltd., Pershing Square Holdings, Ltd., and Valeant Pharmaceuticals International.*

Exhibit 99.5		Letter to Michael R. Gallagher from Pershing Square Capital Management, L.P., dated as of May 5, 2014.*

Exhibit 99.6		Letter to Allergan, Inc. from Pershing Square Capital Management, L.P., dated as of May 12, 2014.*

Exhibit 99.7		Letter to Allergan, Inc. Board of Directors from Pershing Square Capital Management, L.P., dated as of May 19, 2014.*

Exhibit 99.8		Letter to Allergan, Inc. Board of Directors from Pershing Square Capital Management, L.P., dated as of May 21, 2014.

*	Previously Filed.

Page 7 of 7 Pages

EX-99.8 2 d729305dex998.htm EX-99.8 EX-99.8

Exhibit 99.8

LOGO

May 21, 2014

By U.S. Mail and Email:

Mr. Michael R. Gallagher

Lead Director

c/o Allergan, Inc.

2525 Dupont Drive

Irvine, CA 92612

Re:

Allergan Governance Failures

Dear Mr. Gallagher,

We are in receipt of your letter dated May 19^th and Mr. Pyott’s simultaneously released letter to Allergan employees. We regret that you disagree with our statements and can assure you that the purpose of the letter was not a “blatant attempt to isolate” Mr. Pyott.

As we have previously explained, Mr. Pyott has a disabling conflict of interest by virtue of the likely loss of his leadership role and employment at the company if a change-in-control transaction were to be consummated. He is not an independent director, and therefore should not be leading the strategic alternative review process. The Board must recognize his conflicts and that of other employees and put in place policies and procedures to minimize the risk that these conflicts interfere with maximizing shareholder value. Indeed, there will be times when Mr. Pyott should in fact be “isolated” from the process, and when independent directors should take a leadership role, much the same way that good governance requires that certain issues be discussed in executive session or managed by a special committee of disinterested directors.

We were encouraged by our first discussion when you told us that Allergan’s board “has an open mind” with “no entrenched views,” and will show a high degree of “professionalism” during its review process. By allowing Mr. Pyott to be the only spokesperson for the board and the only source of information for the board from shareholders, the board is not showing an appropriate degree of independence in this process, nor is the board able to receive candid feedback from the company’s owners. Mr. Pyott’s comments in his employee letter further highlight these concerns and demonstrate why he should not be leading the strategic review process:

“Valeant has announced its intention to hold a webcast on May 28th to improve the terms of its offer to acquire Allergan. You can be assured that the Allergan Board of Directors, and the small team of Allergan employees who are dedicated to dealing with Valeant and Pershing Square, will be ready.” (emphasis added)

Allergan, Inc.

May 21, 2014

Page 2 of 3

“You should be prepared that this battle may continue throughout the remainder of 2014, and perhaps even into early 2015.”

Mr. Pyott’s framing of the Valeant proposal is disturbing. Valeant has presented Allergan and its shareholders with the opportunity for a substantial initial premium, a large cash payment, and the ability to continue to participate in the material strategic and cost synergies of the combined enterprise. This is a strategic business opportunity that should be explored carefully, not an invasion that requires readiness and a counterattack plan.

As you correctly pointed out initially, the process should be about the board’s thoughtful, unemotional and rational review of strategic alternatives. The Allergan board should independently lead this process rather than delegating these important governance matters to a team of conflicted employees who are “dedicated to dealing with Valeant and Pershing Square” as Mr. Pyott highlighted in his letter.

Moreover, Mr. Pyott raised additional concerns when he states:

“We listened carefully to investors’ perspectives and heard that they would like to see us harnessing this financial strength to create even more stockholder value by, among other suggestions, either purchasing growth oriented companies or technologies that fit our strategy and operating model, and/or buying back Allergan stock.”

We, too, have engaged with and listened carefully to Allergan’s investors and analysts. We did not hear from these constituents that Allergan should pursue “purchasing growth oriented companies or technologies that fit our strategy and operating model, and/or buying back Allergan stock.” In fact, we and most investors believe that paying a premium to acquire another business in an effort to thwart Valeant’s proposal and/or repurchasing shares at today’s premium prices are more likely to destroy value for Allergan shareholders than enhance shareholder value.

If there were highly accretive transactions available to Allergan in the past, the company should already have done them. Similarly, if Allergan has excess capital that should be returned to shareholders, it should have done so when the stock price was 40% lower during the second half of last year. We do not believe that share repurchases at current valuations are a good use of capital.

Lastly, we agree that Mr. Pyott has done a good job running Allergan during his tenure, and he has been appropriately compensated for doing so. Today, however, the decision for the board, and ultimately the shareholders, is to determine the best path forward for Allergan. Mr. Pyott’s history at the company is not a relevant consideration in determining an appropriate governance process for evaluating Valeant’s proposal.

Allergan, Inc.

May 21, 2014

Page 3 of 3

We again strongly urge the independent directors to retain independent counsel and advisors to carefully review the revised Valeant proposal and to negotiate the best possible deal with Valeant in order to maximize value for all shareholders.

Sincerely,

William A. Ackman

cc: The Board of Directors

GRAPHIC 3 g7293051.jpg GRAPHIC begin 644 g7293051.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`?`(=`P$1``(1`0,1`?_$`)T``0`#``,``P$````` M```````&!P@$!0D!`@,*`0$``P$!`0```````````````@,$!0$&$``!!`,! M``$#!`(!!`$%```$`@,%!@`!!P@2$1,4%187"2$C(C$D)1@F43(S1!D1``$# M`P($!`0$!@("`P$```$`$0(A`P0Q$D%181-Q(C(%@9'!%/!"4A6AL>%BNEA6RJ<]@Z@>"^2F))!/F# M#MLJ);&%>9+YMP2S,F>/N,<:VPD!K*4@[$\(@$::DZL%R[L9YV1/%,C'%M@" M34,I2#L_"(!&FI.K`@_#/KFK\N]057Q]U"JWWG@5QIL2QYV[;T@\`ZH>B+K" MI.;NO.(2T,G%/"=)K<2P&8R%,_BR5A9>(?#;=2.I;D[>3V[XQ;@D(,T92UD1 MU_EQ/Q#^VLOM9`P[HG&VS0E/69&M?DSU)\0^YLWKIIA$PB81,(F$3")A$PB8 M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3") MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,( MLR>E2?2\'%U.\>=QZK;$4*>W8^A\;EQM`V7M500`8$?3:/>2I%B'I%K"T5J2 MC5F#.BR1X;(1+X8SSQ"<>5]V#&YCL81J8\9=`=!3I4M4#7#EC,W1N8Q!MPJ8 MZ2GT!T`9SI4M4#7$%CK'9NFWT'WY_6KT'G9=EOE:B^9>D/-GH@>V52F='(YJ M9)B1`]A.@0)*Z<*]'\B(E#88G9$::,2(I`Q@VT,#O;SC=>G]]@2'F#3B:.12 MO*4=.'RUR@7+T_W#VV0>0:<)4''R-8YS:.GLPZZ'"W MN;!EPW&8Q\])&MFC-KTAXEAMR[))W`@$L=H)T!DS`GQZ:JV7N&+&\; M))W"0B2QVB1TB9,P)\=::K3^;%M3")A$PB81,(F$3")A$PB81,(F$3")A$PB M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3" M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%CF%[7P'V>SZ>\UU>]W M*(M',9(CEG4@("4M7).K5?<_`AR,-?J-((W#6P*!-66O]$L8B=@&E@/?96\T MWOYXHW;&=&Y8!D`"VNT^(XL_SY,:X(WL?W"%S'!D`"QJ8G_*+,6?0\6Y&OE! M0/'@/-.E`^;O2GN+^QCG70C69(SBO9XKVMT"/YIZ5K47IPLM,:"Y\;(A<&/EW+D)QK&8DT9CXNTAQ'Q%%ROM8QN M1Q\V]>MRA6$Q-HS`K7<[2'$/U%%Z=>8?!U5\N],Z'U>!]!>INL3_`%:&A8R[ M!=QZG%WV!F2JZAH:`LZP1:=`NZML9$M_@)D?N[?>`^++VW4M,_;Z=G%MV;AO M0E(SEK7U=TR#N`0)/$M3D/$\US M\2%J[CW[V6`,:=XR#N`8@@Q)!8\!3B>!=;7Y=[VX#UP2#L%<1U:&YY;S@X^B M=H<\Y5>B)0A`L,NMW6Y5B&CE!6!]Q*8PDO\0:34M"17'E+1I6B/N.,6 M,M\;][WO6M:UGA( M`/0?FFO4?T5S>K5#I/G+F)ID]ZAI`)+C79IOFLD`['-6 MGC9!;S-9F9.AEE-2KD$M23[*VW^($\V1]MHG#E7;]HQOV]IQ8AY5J7ZZ,-:% MR>BYV9?R;)CDV]IPXAY5K)Z4.C!WH7)Z:UGV7C5-]M4_D?O'PAUNKU?TC5:L MY*\&[Q%H(,I/4*08_LN;X#WZ$%_%D;'RRQR([@QP)2&YBJ3"%%"Z'-8>9=7+ M<&AY_P!LOQ1+MJ&7".9AR`R`*2Y\XR_KHM)C;XWT"0K]]72.C4HM[<):`S(]+L>I0+6;U#%F+TFMR/,X4.VD5)J_-N;T*_SAGMZJHY M,I)W^&D9/W"?H.VZI/-]RV]NV;G_``"['=R`-'/1Z?%H;"EV;K1;!S/F?+8U"#K5V7HUTA":_1 M>7\[K@>G)*>L5DFCQV64!M+V(UM1*]H:94M-V;.U#%E"8!$HD`;LO-O-'FP'TE9HR(ZL[S/B]&O\`)SDHPRU* M=EDJE!1$M%?J1+NF"YF)_FM)9I6Q,(F$3")A$PB81,(F$3")A$PB81,( MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%D-1^:/[#^J2?0_/L0Z,-_7UZ%N:8Z'HUKNT1^83'4#U?-*6/%%>G:#`, MLL4J2,T+$3XP[QS+?Z^G?VL8'8OQLYLGQXCR'2-/U=0-'H-?#$(_;Y$+.?)\ M6(_UDTBX_7UB&VO0:ZLWHUQSQC3>(>B^M=VY+>KE3^>]O""LMM\Y090+7%R^ MSE$&;LW$CSRF%'E-/EKTXC=;Q1#(-^W(BT0^T:$ M\ST9F'-^@&ZUAB&2MYX0)`QD`8G M4+R41(&,@#$BH*\?_$WGG@'+O2_J^B6SE5)?[/P7JA_3.*="L\.W,V:&\Q>A M1B;O34<\D["[(DUN!HMS8M%/5J(T*T.+!L,*_P".TIWRL2QCV;]V$HCN0DX) M_2:AN0C44T7$P<;%Q\F_"<1WK;3']H5QJOM#T MM%:UY+J=D/GO#?EB33]Z$L+<-(G14-ZW[]'+WL2S7RRH&672X)Y+D?5XI]LO M>G9(C;K$[41[@._>`.,7VQU!X.?_`!^#98A'W4#*O@'$/HCJ"/U'F_!>@_-_ M3]3ZGWCJG%*!7++9X'CD?%1MO[+#C,%,=CF?.O6[A&AFX$J1?90@C;+K;ZN?'W"$I@B$O MMS+:)\"7:G%GH^AX.*KF#W.!N!H3^TE+:+E-ID[4&NTF@E0$Z.*JC.X_U]<* MYP#;NFR?M[W3Y:XBQ.R5MDZ'RGTW-4'BG/YJT3;\K*2T.+^V9J3IE>.L/8&^Y^^,5V^RD_SJZ]D\,@ MKQ=*?UB$/>I78:#'2\#7;[&BM%JD*=87A";%SR[0[KC(UOH4T9'CE;">6VZ& M>.T6&\.^G:U9;^,+LA>MG9D1TEJXXQD.,3RU!J""L>3B=Z<;]J6S)@&$F=P= M8R'YHGE0@U!!6:#_`";U2J<^WQWG?J5[A_F]AHS\V)K-#C&^I4"H'OO2$]1. M6=GF+-L"CU%I1A#,8<;`R/Z M!*U<>1KD!S_DYT9^QJH3#19MHL+O3NW6*0&YS69Q$>P7+R^Y.8*LQOQ)+V(6 M]]U6_99N)BB.-C^>>@`(;1ZR-!1R:OT0^X8.&(XF*TYU81(;1SNF:"CDU)Z* MY/!WH3I?JOS?5_0G2*#6^:L=1F;18.95FNS$S/;=XXF9(C^<6F9EIN*@7RY2 M]086IMO;8(C20)`9/V]+TO>].%>NY%@7KH$=QH!RZGC5^5&6OV_(O96,,B]& M,=Q+`/Z=`Y.KER["C46Q\UKYLY M(B'[;`$2G(ZG_%FV-Q)#\`15>;_KKS+)>.:_9[%SF4Z._P#U<]*LS%U]4>?> M)N$#](\V2*Y4>PM=R\LRC' MGCR9'T^4@^G(]4^T^SU&2AQI2K\\]!=0W-5@)N19T^#+2<*_1ZK=Y,YL5Q*V M1I\PK0ZMZ6XQ]]*5(VV<:,]M[?>E;9Q&1('1PP)\)?&JWX^'"1CD=S(E;9Q& M$,#+9;)%+% M(;4T0,2.\E;+X[[2]I6A6MI4G>];UO6\\($AMD'B5Y*,9`QD`8G4%>5W]@OF M%5H\A\^\5^>^-05?Y/UWLW).2=",ID/#Q45P/A%8M MM8E=B'`?9YM>>M'X<2`I]ZS]FD?'XR$\8RW%1+;QCO^JS*RHXPCBV6-^31B.` MX`GZ#4J[,S(8L88>.(G)DT8Q)8#@">G(:G0+D>+NO78'H75/%?5NMC^B^L>8 MN=\5L=Y[I%U\.O-RDEUD:WK51[G$Q1!D9"WBN+J.S6&M.[*)K\G'O$ZV3]Y\ MB.#.[";<01+Q_*3S'/4@UJ"H>W7;UN[/VZ](W#:C$B?-W\IJ7E%M34 M@AZNO1/.DNNF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8 M1,(F$3")A$PB81,(F$3")A$PB81,(O-,OS[ZF(9ETMWQ3+LCWAGHHVUV^0>T M+7V&YY/[7(4E+"CJ8ZLP7;;Z?QYX72$_'3FQF/E\Z<#/(-:G($_5PZ?V_P#V MZ:+Y27MGN9C(;CNEE"YZ^`=@.4='_-R%`KUY+R[KM<`]"-7ZQR,KKHD[8I.E MHBK4^B;KX\JFP-:CX"<(86-%CB,%A_IACP^C6%IV@A*VAA][UXF+EVAD]\D] MR1,0)Z."6]$:R:I<;<7:M)QKI!D6YL?4 MJEU+?P&;9^D88$YVX6[T6(M2B9`Z.[<7W,Q+4=VHHP]K[ENW;R+;2%F4#(&H M$B>K[M"6HY+49=C7^,]\&M7";E=)D2?L41!=5=[`J!LA35;?NEC!YO!TDV'B M)=(NU0T1"U`M6]LMH?'**=4A*M$NJRB.!F_<6,B\1*<1<,V--QV"+`\!&)\" M>I67]JSSFXV9>,97("Z;C2(&^7;C!@6I&$)#H26%2H$-YJ]'_P`2WRB6:\ZO M$BOAE/K/+[#+72='O$9>67)4^(F!%N,5NS,+-RLJX^*.&0@D<5IKY M(1]-[U$85\1C.8W9/;F9$%AOF[@<0`[`\E5^W7Q&-R<1+,[=PRD),-]P%Q%R MX`):)X`!<*M<3](U:;@I.D#SK,2V6XADW_AE4<'/MW^]*7=C&4&!DTC$0N1(/Y=SR#G2 M3/0JN/MWN-K)^XD1=A&=LQ!DTC&-NY"0D?3N>8).DA%Z%3?D7+NL\XZ)(35@ MT];XI[DG#:&&5JUH>%8FZL,5'=#FOQY?_P`BVX2X6V7I24;V>@;_`)[2]\-; MLQ,/(QLCNS&__3;@^[E21K\^OBIX/M^3AY8ORCO(L6K;[N3"9K6FNGF\5SNK MTCODAU*0M==:VZY%G;67H9 MIT8).Q4:WLA;BK8X]NU9FVVRTGD#+>+1$2),Q!F1NW,QBX<$J7WO ME_8;OR^%JI=B=5+H[G2[,\41*"#RP7)H?H4;,R,%-&Q0HD;8)-%68?'<:2C3 M9;:TM..+5\G577,7)R,,6Z"02" M1`&FXAA*0%2VO,FJC"N8=M1.S;9@GZ[1E^@K=>I&L.7=P;=TYK9*.N!@(8`K M;B7HEZGVMMB35&$+8"?2C?Q,FWMNB8L/D:L2`H?99/ M^RW.WOQSD2GMWMNB8L/D0^TD#XA1:`X%Z*`'C8BQ=`(L$D$KD)E/Z&BV2S9W M.!:A='YB^U61CG?M.WEJQU/:(W9Y&G'9E*]H/2TAIM:H6L+-C*!O'?,"#2W$ M;&),@WYG%'_-H6"C9]OSX2MG(/=O,P5 M9RM0=M06I9WJ5?Z:`;^^K>ZA42P#9H*6HVV%3*$@R2'20I/4@EYR.+4KY*`; M*'1]W&/:_9>.NNDGT/Z7%>6/9/=/VPX1,=_W`NBLM-Y)AZO M4S'<^T_H<,>LZU[-[M?>K]NXOX]5Q&&Z;YD@8N]W/FOJ:N]-JUE[S3S0'#U2 M/'28\JOCQ/-RGF78A%S4Q/!(G6U,NAM,(2\3TKF;?N3N1Q]D8VP_G=YL[L*- M'J=>@J>U=]QOW;MR&)LC&U%_."#-M=HHT>IU/*-37_I_R.9W&(YC_8AYFHD5 M$>AG:+S?I'2_.G0B%@98M^X68C<8QF8GTS#. M!(:$AZ.-?@VY_+MX[!VR!*ZUT7F$OPKF=WJ%&1S7S[T.-A=]1J?X8TD78;!T M),(=(PD`3.JD!!1(%ITE00T8DAYQM\IP4?3BF]?,KMR(CC2B!&!UI^8\GHPY M!Z.RU89O9&Z[=CLQ)1B(0(#AM9'D#1H\&>CLM=9N713")A$PB81,(F$3")A$ MPB\5/=WD"D<9\E^U;7Q^"M4OTCU5UGADEU"\2DS/VZ]PU/D.R\GK4T#%6F1, M.L4)S;EM27*2<6`,\R+7TND/L;:TGYIX^5AVK.+=:L9R#DU(#CB:L#4.S_%%_P`,;D#W&D))G+)+.[#A8IE9AY*&&M?75=N8 MWMUEXQ`?0#4G\:DZ>)`.Z_>Q/:L=X1B'TB*&1\?YDZ=2P,C\E6SV`"U%4#U] M6JE-7"RU&5ZL%T3D#9A/.*0S+6C>VN"6B6E2$D3MMHT9,C#QL^*TD>S!!$D+ M'$=8WLJ&'+*A+L9/F>.X2%6<^F1YC@VH\',,&>;;E]MF>J3G M\3>G=.MKUDC[EERQ[M\B`V38>63'S&).OF\`Q&G$+!;]XSKF'>RML!V[NT>2 M;$"9@2/-Y]`6BQ!I5P5.*;[DZ!.0OBNV62G56#H/I@^5JMGZ36FIZ]5"L](? MNP59YG19%N/-`F^*V6_\>E M7WH?!*))L/7G`)ZT_I,RS66ZWYRB^]GUZ6J4H].OJ-L]@HOFG!>MW+C[$[1[O8_5#?;Y#FRYF3FN/< MWX#VASD8'5H^I/H/EKG6X]UX,RT#BJV='@OO%C-/MB.-*KM>X796K=VY$$3W M&6U_*(EGJ:UU56-[K?N8MG)NP!%S>9;7\L8RV@U))JS_`-%(J9[IMO3Y>F5. MKF\F@'Y3S!=_5LWTT\"T7&B3G/X/J$US^O:YM`U^P1TQ91G(^(1+2QB#GOQ1 M#@=,LNJ-;4T.9D2C'9*T_;,R6D7`)'EB"_"I<]`K)9V281[M>C[;4?)%;]()75(@I^9^[SFSHA)6\=$HM M"+*@KA=6JQ2S2YP*"2\-+'B#?:3K;_\`K5HN9%T8<;\`.X1$D,>-2T2Q+!RU M#S6B[EWQ[?#)MQ!O2$20QXUD1$F,BP0TEA: ME9)9]\PG>M]LVK4(R-#YG#DQ+A@VC@N=5CE[GDFWG7)JF^5Y:N5&B2 MLOWKTIW;A M^>V/@OR.?E7,.WD0$>Y*9B0(R.CU$7$A0:&H=^"1]RRYX%O*C&)N2F8R`A*1 M+/40W"4:"H+D.YT8ZX[IW>ST;L/G#@]+#K(=H]#%=3=&N=S1(&UNO1O)ZF!9 M96-!A8P^&,L=OL&I=K8`GYHJ$!AFDKVO0_VU;^6MYGEGRL MY-G%N[32S7/D'')0BTU$Y MZ6 MX;0L1CN-)/MKQW,]'T;AU75[V9;OR[LK0QXQW'RR?;7CN9Z.:-PZJC*%_8_9 M.C"9.?JEL`0XU$2.Y>=Y<=!2[*2 M6-"_>.>:U\TM:5F6S[I._C6[T(B,Y7A`@@T!-"SBK-T6&U[Q M1&W*,@7`D:'459CR-5JKV5ZH:\D4"B]),JSMKK,IUBIU;H+HA"D$TGEI0LS+ M]&ZIIAM*U'1_,ZO#/RYS6O\`]$=Y7_5.LVYN9]G"$V>,K@!Z!B2?@`NA[AG# M!A;N-NC.X(GI%B92^`#^"RY-_P!EQ6O/OIOK]1Y8JPVOD_=BN0\:H'YDFLOL MT0;1:9TVE7,9<;''G!@W;G,^9/")0PKZ1PR-J^FU*WK%+W>(Q9Y,8N1!Z_#A:057N<]$U56P1[`R]]@"87H0S[&B M6'TRR?\!JKZ1XMP*PTY3XO1^.R%BLENA]22FX#MK].D+; M0*K8S6&G"_S/NL@-)0O97RR8]R;*ABSCYC:W28&DB'$1U9Z&M0I#W;;EV\.Y M'SFQNDP-)D.(CJ0#0UJ%'>3>U;9T+G7&^IR;?^VW.40(R M+;0[&3[2W$>7HJH^YY)-LR-O_=:G.,=LRVT.QF^TD?F'E/)5_%?V46"G^=/' M'H+ME$`AZWZ)FZJ;U:6CX:PU"&X=RZVH1I.H6*$L M=OGX&MP4;T:R5>W:K5QL('JV\FH7">LFNR9O/>B=+ML/S::N?'K8V,L8ZC=+ M1$WA9]89>>4+8!6U-M.?EBO#NVY'N-ZS*=O8-P,1$L2"3M<&KO4D=/!7Y/NN M3CRG;V#<#`0DQ,9&0B\2`7!\Q,>8ZBMVT;M7;ISUYU_@T^KD;-#Y/S_D727I MB/@[>):9:*[%-=IA8N%22;;"X4.1KKW,1%O$['6V=HQU*&F-H3O>F%W,^[-F M9M=H#<6$@6)(`?<0X:M*O1ENMW,W[PV;AM=F,1(M&0+2,@`YD0XVUI5Z,RGG M4.X62C>E_+?%(Z(@S*YW:/[L99)@Y1VIF$5R>I5ZPQ*85+#Z`5HE29I39/Y" M%?!MO6T?3>]Y;=O7(95JS';VYB3N[^4#2K<5*_DW;6=8QH[>U=$R7=QL`-*M M5^(52=W]+=PI/J+DW">0\YJ/0HJW4(3HMMU)$304^%6@^V\YYIMZWK6];UOZZWK?\` MG6];U_C>MZSH+JKYPB81,(F$3")A$PB81,(F$3")A$PBI;LW;8/B(]-E++!S M\E7K)9GH.=FX(=HYNBPPU?F9T^[6`'[J#GJK#)B4ZD'14/.ACNJ)4WMAEU2< MN3E1Q=IG&1A*3$C\H9]QZ#BV@KH%DR\N.)L,XR,)28D?E`!)D1JPXMH*Z`JF M&/8(QT!3"(^QCE-R-;NAMI^8L6:/#NQ#ZH>!IQLAMU12 M=EMZ0EAM6E*6C''W.<\<94+3V39[GJ^8]+:.7>K4"Y\?=KL\49D+(-B6/W?7 MP<./1M81>3[JM0<1/^3^CHCMCMY:H-9DB/V.U(,E;F#PHO9LLZ?(KI0[6FTF MZ9BN@4]@*P@&[VK28J5%6MO2U[3J>)[E'.,QCP+0B]2SDD[1QI*($@>1%%9A M>[1]P,_M8$QA%W)9R2=@T-)Q`F#PC(.*JM@/9P$Q!RTQ$92K-4Z"$,T2&L=^QP-\%DXEL=3C8Y"H[\A1#3)(RG*A[I[WI$@8\A(0E-I2VG9%A(U&NXD1!($@-S M@$+I)#WK38N/[M-%TN;5#\,!K\S*."2#),Q+0<[/1D-HM-;_``&YH(U@>2_) M2.VT7IS3:F5.-O[TWNK]\MMDR-LMCD/6I#@.S4UH`_*A6;_^DMB.9,VBV)(. M`23(4JVVAK0#<[,2"5H:R]FU7.'/]I;J9MI2F`C+!'U"FSD%.R<\Q-GABPX, M!,[*#KTE(2+)[2FOB1H9;JO@EY2?HYO==SNS@??3@30';$@FI`#'0FHZ<'XK MJ7<_L>W'/N0):(.V)$C4@``Z$EQT>CG55;'>OJ[8W*X33ZI(V>`N=^/Y55YL M612'O?2!*S`6W54M<0;'-RM,,8B2)I!WY;>UQQE??&?1IUYE.Z?W/7Y&:;%PV]CR\NVH`)D33BS;?CP6C)SIX]PVQ;W2:.WS`"1D9`C M0LVTU.N@"J>*]O5J?AC;)"4"R%P:*@9:HY\B2AP3R%P3_)F[5$2<:\XIR&)B M&.O@.L+6MU!R1B/A\?\`1M[/#W07(&Y;MDV]NX'<'+;=SC@PD&Y]*/FA[P+M MLWK5HFULW1\P!+;-SC@PF"-7Y"CS83TZZ7:[!4D\JNK][9T'N M9FY1W,[;2^[@O1[M,W96NS+?&[&#/5I&7F9M6CN9VV%]W!0[VCXO@/55>KED MK5D=Y)Z5Y&Y)S/`>^0T>.?+TJ8D1M,2U3MD2]I(M]XW?QF]`VBL'?,*4!5\D MZ;):8?:UY>)')B^ET:'Z'F#Q6K.P89D'H+\1Y9?0\XGB/P;)\FW;T#?N)UB< M]-\=K_#^NC[.@K+3:O:V[97C":\:1#*MM=?2&(1$5:W["_4(H`O;D@(`^T@K M:7M*3J6+.]@(2%/%N+<.@JK,*YD7+`ED0$)BC:(]RU,,Y-8!ZBOY6-&KPT+KD_:7+&8;@B;UJ89S*ML$EP`:&+&@%0VW M0NMW\XYY4>346K_IMQU M7QU]$Z^B=:UK=9LPQ[4;-M]D0PJ_\2NC8L6\:S&Q9#6XAA5_XE37+50NFO5>$=Z%&U@ZE@7-8#&[$)49.2#F9&ML2GQ_*;A39:/8)='TK[:WV4+ MWKY(3O59LVC=%\Q'=`9^+R;XR3$=\1VB7%N7@J\8\T>?QHFQP(_(*$U M"6^T#7:S1**\%J.F[>);=WT>S'A_;^P]-MW??ZO^3\=.[DOH3O>W=:7E/V.( M(F';CM)<^+O_`#KXK/\`MN"(&V+4=DBY'4%_YE_&JY@OG?A85G9N07***%96 M+))W)N4$KX(SG[MF3VY>4L[C##38CT^;,M:.66MM3_YWU)TK3ZE.;?98G=%_ MMQ[H+NW'GX\?&NJE^WX7?^Y[4.^"[MQY\GXOSKJN7%\&XQ"D5HN(YC3(TJFW M:V](JA`<&$P[7;]?6I=F[7"'6VWI0%AMC-@/3(%-_%TM)K^G-J^\Y\IQQ<>+ M;8@-(D>)U*E'"Q8;=D`-LC(:T)U/Q9C2[<_?4QJ&$(0*FX3C23)'2=:T62G3KGR7KZYY;Q,>T0;<`#%VZ/K\UY M:P<2R8FU;C$P=FX;M?GQ70V'S9P&TP%5JTYQWGA=>HPLF!2HIJKQ8`U1C9IA M0LU$UK4<.(N#AYD57VC`QE-#%-ZTAU"TIUK7ES#Q;L!;G")A'3@W@W/B.*\N MX&%?MBU=MQ-N.@9FZ!F(!XC0J43W(^96>EP_.9RCUPZB5YF''@*I^G,C0D(- M7Q-1\(+$@AZ':CA8R.U^,TTSI"$C[VU]/M[VGOF7-0HP0UL MZD9!VBTC"QXA,=$?DVAFOQEBL4C"1AQ`@8 M0OX_+7UR^6'BRB(2A':([?\`UY>"OE[?AS@(2MQ,!':!_;R\%]9KS-Y]L4FY M-37'>?R$N]:WKT[)/5R/2:Y=BJTNFF6Y9#33;JK*?4G%1I)V]_DD`JVRZM;> M]IWX<+%D23"+G7KPK\$E[?A3),K<7.O6C5YTH>?%3:_B)0_EX'4'P443YTX4FO2U3WR>C.UR=;IC@`'(&Y MV2PG#RD[.V2-6SL:6E)B1$;?)>>2I;SJ-*7O:O\`.2.)C&W*R81[4RY'`G5S M\E[]CB&U.P;<>S,O(<"=7/Q`*Y-CXIR2WRLG.6CG=3GYF:HG\83$I*PXIA\I MSK]3W-;I,@4ZA3Q=95+*V0H-S:F5/*VK:=[WOZIXN/.WXW,+%O M?\D!)X;:OZ>7@NFM/G+@]WE96T-K2GZ:SR>)C7);YP!D6KX:?+@O+F#B7I&=RV# M,M6O#0^(X%3"5YESR=!KT9-TNM3$;5`I&-KL=*1`9X$3'2]=,J,J"(&4TZ,D M.2JTB1'D-[3M#P;[C2];0M6MSECV)"(E")$/331PU/A3P4Y8F-,0$X1(M^D- M0.-I;X$CP74QW%>1Q%L;O43S>FQ5P:)#-;L,;`1X$D@R/J">?`&)>%8:^A05 M%0F&9<^GS;C$Z&3O3.M(U$8N,+HO"$1=&A^#?RIX441A8HO#(C;B+PT(#<&_ ME3PHNK@?/7"ZQ!RE8@.2<_BZU-U'5`EZX-5XK4!)49)LU(HIYD,L9<:16D'6 M.0=2$IK8Z5&O?1'^Q7U0Q,:#[81#ACX:MX.EO!Q+1)MVXC=':>HU;P==B9Q' MD,AI6C^;T\SZWJO=/THF$"><;Z)4X^.B:Q=67'&E.,66`BH@440M&TO,#L(; M1O2$Z3GOVU@OY160D?\`(4!\5Z:8F>LAH?&@4?A_,_GVOSTK9H/CG M/HF;N!0$#&56( MX]SP2L0T)+UJ*KG[7BWX(&N3\="Q$S7QXDD=X!$)(Q5``7Z3OG/A%F_-W.\EH M&X#>P]R.MZ*4-O;>U[3_C/98>+, MDRA%S)_BS/XLO9^WX5PDSMQ),MQI^9F?Q(H3Q4C7R'EKK,Z,_P`^J!0UFG:U M:)\8R!CC!I:R4QF$8J,\8.4PZR[,5AJMQ^@"/C]T3\%C;:D[:1M,XX]B+[8C MS$$^(T^3!E;'%QX&1C"(W$$]3%F/P8-R9<2=XKR>RR]LL$Y0:T?/7N)JD#$HTL_.U"(FI!G[91T;79JV"^T2M6R=HSDLY3IB M:C&#)*LKGF!Q9S]%-7K\@!,P*(TT4EM6DD-MI2O2DZ^F2NX]F\1*[$2D-/CK M\U*]B8^1(2O0$I1=GX/K\^*XR.)\B:E6)QKF].:F!JG9J(Q(MP0+9;5+NDO^ MX+;5D.H:TK4%8YS_`+LP;_\`$^1K3B];5K6]>#%QP=PA%Q$CX&I'Q*.$"&,VED<0,1I#`PP[2-:0TR MPRVE*$ZUK24ZUK67`"(84`6@`1`C&@"Y6>KU,(F$3")A$PB81,(F$3"+Z[6A M*D(4M*5.;WIM.U:TI>TIVI6D:WOZJVE.M[W]/^FL.$7Q]Q'S^W\T?MPE"W,B4@"8NW2C'^%%"5NW.0G(`RB2QY.&+7;0#T\FY=-%*(>`K<%M_ MY3S,AB-%>H%0 M=&AS)P^+877XQ30)=GD7)BR.C(V-]&_W#+/*).3K_B6_O[CNEJUK>5RQ<:8` MG")`)(<`U-3\^/-53P\6X!&Y;A(`DAP"Q-3\^/-?D9RGEL@820?0:87(&E2$ MH6^37XETPHJ4/AI&3,?<6-MYY9TI7P'WE*WOYD!L+5]5M(WJ)Q,21+VX$DDF M@J2SGXL'\`O)8>'(G=:MDDDGRBI+.3XL'\!R7[1_,N:QT=+P,92ZJ)#R[XID MQ""1`#464^.WM>O^7^<1Q<41E",(;9$$A@Q MJXIXU\:I'#Q(QG"-N&V9!D&#$ZAQIK7QJN=^R:&M]LQ-5JWY"+>N[MDM0\8A MW]]JCG(1RU?=;82I5H7%.+%49O>R5,;VWM7Q_P`9/LV'?;%]^[0>IF?_`":C MZJSLV'W;8/OW:#U,V[_)J/JU%]9WGE#M!$D58J?6YTF6"B(R4?E8@$]XX"`D M")>##*<(9<6ZQ$29KI(R=[^C+SJEH^BE;WORYC8]XDW81D2`"X=P"X'P-0O+ MF+C7MW=A"6X`%P"X!<`^!J%P2^7\Q)W-K,HE-8`-!4!F!YB@^0Y*2?HU=T_LG4=$_E*F4RNR/QQ?R=SR0U`I.V]\?N[DTQ MR]L:7]?N:'WMO_[-_3+.W:=VB^Y__;1_%J>"GV;#OMB^_=H/4S/XM3PHN\RQ M7*EO0]'ZIT;CMTJ?$.MD<-ZR:$(90^F-5V'MH<#8H>2#F`!Y^M38Q`DS59QP M'\"58;VR4N/)>T.\T]\'$TWX7+EHQM2,+G`^'`]#H51DV[MVR869F%W@?"K' MH=#T6<_&OLH_N1]PX-WBG#<0]J<1%!3VCBRSG"XB:ARW%"0O:^*31:6G+YPZ M^.M;<`/;ULB,(4J/D$M%M?[*<;*-TFU>&W)CJ/J.BSX>8;Q-B^-F7#4<_P"Z M/,%;US8MZ81,(F$3")A$PB81,(F$6=.O=>GHZ>!XYQP&.LW<;+')DDHDDO/U M+E-2(>=#7TSIBPW&GVHEM]EQN)B6W&C[$>UMAC;3#1A@F/(R)B8Q\<"63(/7 M2(_5+Z#61Z.1CR,B<9#&Q@)94A\(C]4NG(:R-!1R+NK$7)0E<@X>9L)]LEXV M*!"E+/)BQP,A8)`<=MLR8+"B!0HH)Z0(2IW;([+;+7R^*$Z3K6:;<90@(R)E M("I/'K2BTVXRA`1E(RD!4EJ]:47>Y-33")A$PB81,(F$3")A$PB81,(F$3") MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%573*3: M+H70-0%OE:E'UZW.3UG_`$64-BI"(:(2IE8[2 M_P#&U_#69,JQL/,=&/TT&%H:^QR.[ M;79:43?V)#HMJZ*=7XP)N5JID9)UVM5RZZ2D4Q_\?]25M_[*_P`4?YY+7M^3 M"];86X6X1F#*)\[R,F`>)#`2T/$DD%@L6-[9F6;UH-:A:A"8,XE[CRE,Q`>! M!B!+B?426+!^GLOE?HDQ?>Q7!F[11`W0S.:D1$=(E2J4@*Y]=N<6,4W2A8]+ MD,<]%T\QLIMIPL0TM]AUIH%.B4/S'MUZ.5=R"8RW[6;G3:%;' MVR_#-O99VSW[-H)(])!!/EH0U6<$LPBKAJ'';/7+3V6X;D8EE'1Y@:;"H8;@ MRZP6:#5GJT\W9))ZKHD-1=B6TP8\R.PH@;RN`=2!6I,8DQT'J)VZ+'^QW)V!&9MB M_&W<$9"L@9R)$=VT>6,"8:!]Q.W1=S0/*UTJG1J=;3+?%;A*[/&6@2+`>EE$ MU`89&?Y\4-U8!M7W?L*3^@,_Z-Z_'_&MQ_;;MJ_;NRV-$DT= MXN9^2.@V><OV[EJ9C"$9N'((&JG$ M:!S`:QT:4-7:;-)P(5-W:#;6%/5-4;("2!=50*"^X^\6)'H5IK[3A;^T5XV# MDV\C=+9"V+4(O#U$Q$7W/%B*,.0%&)56%[=F6;[W.W;M1LVX;H%YR,1$2W;H M,WE8%R=HHQ)5;S'E7J%ED`Y1JQ@94+ M-VW?N;M^YAP)D&)D=KU-0!Z='(9M=CVW,ACWK-^[NW[V#TD9Q8F4MNX!Z@#T MBCR#`5Q)>4[Q(T>W4YV6JNW[AR'@O.U3OYTH\57[+RJMW",E[J`-(01[):RC MID)IIK6Q2"06WM*?&>VVO54O;;YQNP!#<;=J)DY<&$2#(>4]!P3] MF,;;;[G;M1,]Q?="!B9#RG2@&CQ)K$JQ`N$6L;HUDZ(O=2<5-]!I-L%K.GE) MAPR*O5N@4T^S..;J^R'I"3$MXTJ@#7Q=;EQ%*W)J97IM-HP+PO2O-;K=C)GI M02&[TZU$F_4'WM17CVZ^+TKVVU6_&>U_+02&[T>KS">W]==[46M\["[B818C M]E>-8_TP!3^@4"XE<0]7\1).G_.WHJO@MES-)F"VTZDZ?<(O:F6K[QN^--)$ ML=;,5L8T;?W6MM%M,OHRY.,+S3@=M^.DOH>GXY@X\O$&2!.!V9,/3(<.AY@_ MCB#TGC;V5(=PD;AP3O=.%XC[5XB*%KL_&-G.EPL]"ENJ#A>W<0FS$M.WSAM\ M=:VX"1D3C,8^.!+)D'KI$?JETY#61H*.1,^0\A@.10)P()LE9;399)5BZ M%T*Q*9(MO0K:0PTP58+`4PTRPVEMAE`X((Z&@(L%IH01IIAI"-6X^/#'@0', MY%Y2.LCS/T&@%!168^/#'@0"97)%Y2.LCS/T&@%!16QEZT)A$PB81,(F$3") MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,( MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBQ'[*\:QWIF.I M]]H5P+XEZMXD4;8/.WHFO!-E3=(FBFTZDZE;8W:FFKWQV]M-)$L=<+4H8T;? MW&_M%-,O(R96*+X$X';D1],OH>GXY@XLS#&2!.!V9,*QD.'0\P?QUZ/QK[*D M>W25PX#WVGB<2]K<2$"_F3C>S7"H2Q093J@X7M_$)HQ+3M[XA>GFMK"-1K94 M45M4?():*:_V>8N4;I-F\-N3'4<^HZ*.'F&\38OC9EPU'/\`NCS!_@M\9L6] M,(F$3")A$PBSIUWKL^!/A<:XT%&V3M]CCD22MR:'B*ER:I$O.B;Z5TI0CK+R M8Y+S+C<1$-N-'6$YI3+*FAVC#!,>1D3$_ML=CDD/T@/U2^@UD>CD8\C(F)C& MQ@)9,@]=(C]4NG(:R/1R)IR+D4!R*`-``-D;'9['(KL70.@V);)%MZ%;2&6F M2[#82V&F64[2RRA@((=#0,8"TT((TT.TA&K1ER<47 MP)P.V_'TR^AZ?CF#BS,,9($X'9DPK&0X=#S!Y?U!ZOQM[*-[J=<>%=UIHW#_ M`&EQ`<%OMG$G#W#8F4BC'%"0O:>*39:&7;_PJ_.L[$=(V6T622=L?0>@V';#ULZ#;BVVVC+#/DCM,L- MI0RT@<$)A#8,6`TR(*TTPTA&IX^/#'B0',Y%Y2.LCS/T&@%!13Q\>&/`@$RN M2+RD=9'F?H-`*"BMC+UH3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3 M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81 M,(F$3")A$PB81,(F$3")A$PB81,(F$6(O9/C4'TJ%3NA\\N)/$/67$"#IWSO MZ)@06S):FRQC:=2E+ND5M335]XS?6VDB6*N%JV.6/O3K6VBVF7D9,K%[X%RV M=N3'TR^AZ'^'S!PYF&,D"Y;.S*A6,APZ'F#Q']0>H\;>R3NYGW'A'=Z<-Q#V MIQ$4%/:N*+.<+B)B',<4)"]LXI-%I:=OO"[ZZUM?]T>8/\`#Y+>F;5O3"+._7.N3L;. M@\>X\#'67M]ECDR2$227WZGRNIOO.AJZ7TM8;K+[40V^RXW%13;C1]A.:4PP MIIAHPP3)?OR$ACV`#DD?"(_5+IR&LC04A="L2F'[9T&V/L-#DST^2PTRPTAH=E`X(( MZ&@(L!IH01IIAI"-6V+$;$6!)F2\I'61YGZ#0"@5N/CQQXD`F5R1>4CK(\S] M!H!0*U\N5Z81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$ MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$ M3")A$PB81,(F$3")A$PB81,(L1^R?&H'I<&G=!Y_<2N(>L.(%'3_`)U]%5\% MHR9I4P8VG4I3KC%;4RU?N,WUII(EDK9BMC&C;^ZUMDMIA]O)DXHO@3@=N1'T MR^AZ?CF#BS,,9($X'9DPK&0U'0\P>(_!Z;QM[*/[C(7#@O>J<+Q#VKQ(4'7: M.+;.<,A9R&+=4'"]MXC-F):=OO#+XZUM8!Z-;*BR=JCI%#1;7^SS%RNZ39NC M;DQU'U'0J.'F&\3CWQLS(>J//^Z/,'^'R*NGK77K`%8A>-<8CXZS]LGHYN3( M7)_>>I_(ZF8Z\(CHW2UB.,O[#4^RXF(A6G6I"PELK:94R,T6:+*]>D)=BP`; MY'PB/U2^@U/S*LOWY"7V^.`<@CX1'ZI?0:R/1R)MR/D<#R2"."!-DK+:;+(J ML/0>@V);)%LZ#;'V6F"I^?*8:98;2VPR@<$$=#0$6"TT((TTPTA&IV+$;$2` MYF2\I'61YGZ#0"@5F/CPQXD`DSD7E(ZR/,_0:`4%%:V7J],(F$3")A$PB81, M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$ MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$ M3")A%XR?VV_QS\O/_P#&_P"]?_Z5_N][_P!%_P"$OT'^8/U#[HG\A_O3]P?_ M`!C_`-7/T'Z_OG]R_P#Q_P#&^W\?^_\`QW7J_]O-__`"MZ>2_X]_C^6_;'Z_\`R%^Y"OYY_?\`^-_+'\N_ MBB_KW\C_`(_^C\W\;[/Z5^'_`.&_1/Q/TK_QWXV:L+M]H['[K^?=ZMW'=]&H MS-1;,#M=GR[N\_GW>K=QW?1J,VVBU/FQ;DPB81,(F$3")A$PB81,(F$3")A$ MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$ @3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D_ ` end GRAPHIC 4 g7293052.jpg GRAPHIC begin 644 g7293052.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`+@"?`P$1``(1`0,1`?_$`'D```("`P$``P`````` M```````("0H%!@<$`0(#`0$!`0```````````````````0(0```&`@$$`0,# M`P0#``````(#!`4&!P$("0`2$Q01%18*(2(7,4$C,U,D&"<9*1$!``(#`0`` M``````````````$1(3%Q0?_:``P#`0`"$0,1`#\`O\=`=`E'(;O%5W'5J/;N MUMJG(E3?7T>5_9\.4/!;&OLZR%R14&$5FQ+A(G,PEUEKN2$G)P$JGTTH3E0R MQ%$&?`=PURM%^N_7^D;FE$!=*JD=L5/7UCO=:/:TMQ=X&YS6*M>\HH?<6$.S]!!KN5MMMIL_;DMT&XI%K`S6!!UR5@W% MW@E+^,@XS.4I=;.+K; M%M*^.MMHGC_A%ILC#9EH9G\O@D-L:PON2]+\EJ-*LFEO6H]#G%D"V M5S:1FDFFML+@$9+-`X2N7/&2LX(2)\?``!&<>,E.4:<6'FTCV3F^V^O47ON; MZYV7JZ.=.3^MB-9VZJ9QS]578',W$$FS^T-)@S(HLF<=R2M&T+`A5H!C$7G) MQ7B4'`VO0+_L;M9K;J'!0V7L[=M<4="#5H&U&_6))VZ/DNKF/MR%L8TBDWZB M_.?8/`\IT1)YP2_D>0X#C..8NDM'FYG.<-5 MN+-XCVT.Y$N(4IU3#/+V?FQ(LH2A,#2X/)P>SEG+5#H0<,(S42AW3Y`4:F`( MPOBT5T1#[NUL=;=\7$?QBZ.R9;%[ME$43/>V>T+*'VFW1BBI,4(*9-V.AH_??E4AG:P]P5F+#L.,I=?/CO)3@5*T@V7_7 MJH:=X0*?DW(%R9SYWVNY9=M%B(K+4VI6RR+ODU@R!/DECU?U2CK>2J<,-I"Q M:6A=')M`F9\``44#!"`A$G&$KW'8\\IEOR&:[';\I*PUUK2?1I&WTKHC"61' M*9O5``.XE?WQ

H)*$%JCC(D(*4+7:221R$4B;T28HY0J5'`` M6`6<_'05"-=Z!<+)>G'GU_(JL@ZN81%'P;[IIIU:($8W1V/[DZ8ZB:RP- MJZ_XTJ[J+B^T28K"WDWO(AHT%=5#*;!?K!>XH0Z*A.3I>VX=N.BM6FJFNB7- M\$XY3*3V\Q:484A9TR9*(H:<.F:H\3K:W6(R[B\B\W1[P;\&=KFBF(W!61DP407E^4(QR!S5)O>&8E-/-+Z%IENB#H#H#H#H#H M#H#H(V.5[?8CCPT]F%QL#*1-[QF#PQT[K#5F25"Y;9^P-BJ!,\!CB=J1&%+W M-$@49-D4WV>M^5RF_=L[0+ M+2&KY]?5HNRB1RLU0[DI4Q[LWQ?"PMJ1&&?M&4D$:`)>#L@P&@N\32N>+%W.V"6'IU25)6U:EMQ^&MJR`Q M=*GPL"!(0?C!^`B%936#FX:-!M7[LL:D:5+L37VRWU]K[4.RK<-EV=UN3WD, M,?VA-=FT$X92W%\.1T,G$]E^V086%4W'D-D?;U)BXQ6D;8K<]:XG(N*TY=O' MN?%WW

(4Q\,JQ(?\`4*)T+K=W(R=E M"6-,L2-]4U[$V-:>$YP*-;5CBD\F23$+<_(D)4F1RV M_)TG-`EBD+,]K"4U20#Q!&')BV'"V59Q;[F<\&S+-O;R\H9=1FD<=6.R_5GC MYR^.S#-3(:M,*RQK+#`VEM"J&%2-&42I>G$?AE#X,O!)0&QN`CZHE8L/;YXL M*0J.+7A-CD$8Y332='6EX[-M,.3':K4EDB;> M8(JA2)G8]>2R)"?$W$>49A"`LXY>,;6/M87'9!XH>MW;; MJ/U9$MBG1D,<;-BE++GYSKB,.JYQ6J6Z.L;G)%KBYN:ID8C4J9Q48/-2GN12 M@:48DPBLYJ.\]`=`=`=`=`=`=!]1""`(AC$$``!R(0A9P$(0AQ\B$(6?C&`X MQCYSG/04W;+WSURV`WTEG*;L/,UCIQV<8TN=]8]#H-$FI9*)9MKOG+T32&QK M`J2#?"0NP%\81KD[8Q'`/PC)$F1N6#DH0JA]1:1O,?*9R$X%5;690V+`: M`B&Q*J#\=/'M6\U=(+(-J-AX2C$8O?KFG%&18O+AO2U.9)\6TZ MTPRL)"ACNLU#JR#&:.G(RRFIO0A-=S$9H?&(L=<+9;B<=3KZJK8FQ*@BMN4)P<+,HL.RA*F$`D;82VMZT,CJ@WQ6AM8[ONG7*X9W0&O; MPW@G&_?/'?;2)3L/N]*VI[>AR*KN/FO;(,-

EDB\Z!DE3B4$WV5``I$+D M[A*6X*\=:P:I8TV4;MQMO0EKNK!+;#=Y1P[<*ADM66I>&P-H2\E-(%VZVVZV M2N,@?;`N*PG50:]NS_+CE;1!V7LR:8?\(TF0F1C'#K:.Y5IT_N9RX7$=/[^J MFV(=;-0:PTPN3E:C:]1F-''O)=2#CLG9G,VV7U^>3DITGE"S(%BTUI2ID9P4 M166H(;`JDY"(U0J."F5!%YKO>.QW(Q&TG'3^/Y6J[0?BXJ M)<3$+LW[DK\8]<*8?KA`0IY0_)21V==LT/(D%P6HO(5+7`3C-IB:G3BRD)5+ MS1$H$9:1N3XS\A)\F1F#(Z3;'(SH#1+@)HN3=;5BM'D"H*,UDF%\5FRO:=2, MHTX!2IF5R0#FER(H@><9,*"'/Q_7YZ!FJ\L6`VY"(Q9E632+6+7X(2SV!A%@9:H3HN$K3X'AN.Q@*I6ZD4D^B6O6ID=M:,2!HW1V/K\FI= M3]/(7]-DWMU4O#4VZ4W@I:5_5<:O'6YJD),1T1U,;4!BI M?/-I-F%KYX'8;-YW>6O;H:XN(O7.&Z@&VM02K=Y]Q+3!:RO7AVXH^,WCGC9Y M.NT_V-A;M$H[II6\5":[6R4HW%:9LS M;M,OT@(!-\+2'K(XE4F#+[%IAH4X:EN3. M.W-E:6U:Q:MQQV0LZ&.\B'(F^M`?MY?(' M8(W3=RPJ10.3[;*J/M:'+F^ZI4TL1)\,L*DLQ80&$3B>NBD M#'!&4:DDS![I_P`'J$0KH5@KKW=MRIQQY&;5SKGHW4IK0#4#ART=C4^LBV[; MB)`71U1O;/6,/7NLACY4S3JC5;E9U]/8(LJ;RE9`2EB5H<)8H\01DJ@EF9-R.!3];J?T7V*>XG;%P:&[4;1 MMK(YHE%;:=<8O'?+:AU>:3%24(V];T)4I&+U%BM]<6WSG!--`` M\O)V!A;#KWD.WPA<%JVN=8_QW-A897:%M11^,0V37IK3KG%($R8&22U(T\=+ MP^YCK>2(TT:HM8C;1)L8[Q!,$,7;1LLGW;Y]#W40X3PA58WL?@)"!/+>1VBG M-XRJQ@65)@E+(VMR'"861X^,YR+/S\8(S6=COR$Y!&R3&?C7T:KZ2 M.1:;PXGF[3Y+$T<,&K+"H^OM$(KL@ISP6EP/.<('<7;D6!!$9D.2A%P])"'\ MDN4NJU0LD'#E430F1(BD#O5.M?9;2P$^$(2\%G?.?[ M_P!<]##,I]:N>.9)S39GR\G')W%KI70]9-2HHW&#];"N%R&V+C]A8\ M81X]@OZLWJDY*L7:()Y0<8$1\F\7&\\[*()O#G$W=>BC`B1NQ5`5EK=K%A8U M%'C5(BFY7$Z_D[LR/`%`L84+RU(S5!./%V@!^G1;=78>&74I$H62J:S#:>[[ MI+8'QKA.PVP&SMIW);5.R)X:7!L16A2(9L\.=;U1;41.<46 MN4^8SHF=F;E3>YO!:1PDR94=8;B$@LG!R;))@/K%:=TA9OR/K;M;>C;R!R M_?&2KXTUZ#ZN&53<[3!:VA?\<)<5O*W>Q9A`D%42FV1,J-7AL0-D@-2EOJA4 M:G&8[FIDS?!P;CKU_P"+BHN9*[I!NMORU;=\P$EO.5%1*$SO7NZ*+@%;S[*T M*MG4P3^0XEF!2*PS8WZ2>*X22%6@2MGC`Q@69RG68!W/R9ZON^X*BHV(3'9: M)ZC<9)$]8''=6X2(%<-M62>_#D[8"IV!/7525_,5*Z($R%.4(HQQ4MC2.1*F M_*L\.2$Q9U(2#<+4>XTXGK&^1KC>GA5HM3'.%[;L-8LQ;)@R[$32[$N#2WV1 M;#-%G1J'6>VRQS-P<8C(4?%FWZH(6_B==:Y?:+0NQ*.7/<5+?2;`>9XF:$))[K=)4X;6: MRBIXX-H"CLA?$:4P*<8<)B2DWC`$A^MA8S()I15OQ.*65-J;DLBKF7M#%:U; M1HR93^O71:R+"4E0ITQJE2:#!9/P:(`L!0Y1:]?BT$ MZ[*X;--]-J7.40:QUKENO<+55NW<>N.[I4J<3"U;%L3$7C7.6/L'KM#9)Q)R M,'HH@EOA(2E#@K(,KA0(K45*U<+"J#?RI(7@H` M5-GALLA+?04YYN,"+P]%%IL"SGPA#C],5#CDC]R?6O_+7L>O[/C^H_Y/%W?'[>I@3&E>+Q%>#Q^#Q@ D\/B[?%XNW'C\79^SQ]GQV_'Z?'].J/TZ`Z`Z`Z`Z`Z`Z#__9 ` end